Europe: CJEU rules on SPC term

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Europe: CJEU rules on SPC term

In Estonia a patent was granted on April 15 1998 followed by a marketing authorisation on June 8 2001 for a pharmaceutical composition comprising the active agent capecitabine. Based thereon a supplementary protection certificate (SPC) was requested and granted. According to Estonian national SPC regulations the SPC provided a protection term of 15 years from the date of grant of the marketing authorization, that is until June 8 2016.

On December 15 2014, however, a generic competitor wanted to bring a generic composition comprising capecitabine onto the Estonian market since, according to the competitor´s calculation, the SPC protection term ended on June 10 2013. The patentee filed an infringement suit against the competitor and the court of second instance, the Tallinn Court of Appeal, transferred the case to the CJEU for clarification of the termination date of the SPC in Estonia.

How did the discrepancy in the calculation of the termination dates arise?

On May 1 2004 Estonia became a member of the EU and according to European SPC regulations the protection term of an SPC is calculated based on the first marketing authorisation in the EU which, in the present case, was granted for capecitabine in Switzerland on June 10 1998. The CJEU hinted that Article 21(2) of SPC Regulation 469/2009 states that the regulation applies to SPCs granted according to national regulations in Estonia prior to the date of Estonia´s accession to the EU.

Further, Article 13 of this regulation in conjunction with recital 9 thereof indicates that the holder of both the patent and the SPC should not be able to enjoy more than 15 years of exclusivity from the time of the first marketing authorisation granted in the EU which, according to Article 13, has to be interpreted as the European Economic Area (EEA). Accordingly, the protection term of an SPC is calculated based on the first marketing authorisation in the EEA, even if a national SPC was granted based on a national marketing authorisation before accession of the country in question to the EU.

hermann.jpg

Bettina Hermann


V.O.Johan de Wittlaan 72517 JR The HagueThe NetherlandsTel: +31 70 416 67 11Fax: +31 70 416 67 99info@vo.euwww.vo.eu

more from across site and SHARED ros bottom lb

More from across our site

Monetisation is standing at the forefront of patent development, and one firm says AI is increasingly being deployed
Data centres are being built across the US, prompting patent disputes, but Texas’s thriving tech industry and patent-ready courts make the state particularly ‘ripe’ for litigation
Carpmaels & Ransford is set to bolster its UK attorney team with the appointment of Simmons & Simmons’s head of IP in the UK
Updates on Nokia’s licensing strides and a surge in patent activity around battery recycling in Australia were also among the top talking points
To mark International Day Against Child Labour, Matteo Amerio at Corsearch says the people inside businesses who can identify counterfeiting risks must be given the tools and authority to act
With genuine equity at IP firms becoming rarer, securing partnership is harder than ever, but increased transparency is also making climbing the ladder more predictable
Yossi Sivan explains how Israeli judgment is a pro-brand owner departure from the norm and why it sends a strong message that corporate structures are not always a shield
Halim Shehadeh, group CEO of IP firm CWB, says that in the rush to discuss what AI can do, IP firms are overlooking the more important question of whether they are ready
Caitlin Heard, who formally joined the firm from CMS last month, says she is excited by the ‘energy’ of the London office
Ranjna Mehta-Dutt, who moved to Chadha & Chadha after 25 years at Remfry & Sagar, says the firm plans to expand its life sciences practice through targeted recruitment and dedicated teams for bigger clients
Gift this article